Document is current
Any future updates will be listed below
-
Authors
Mak, Lung-Yi https://orcid.org/0000-0002-2266-3935
Liu, Ken https://orcid.org/0000-0002-0453-3168
Chirapongsathorn, Sakkarin https://orcid.org/0000-0001-6924-8504
Yew, Kuo Chao https://orcid.org/0000-0003-2005-675X
Tamaki, Nobuharu https://orcid.org/0000-0003-4634-6616
Rajaram, Ruveena Bhavani
Panlilio, Mara Teresa https://orcid.org/0009-0003-4649-7366
Lui, Rashid https://orcid.org/0000-0003-1277-9595
Lee, Hye Won https://orcid.org/0000-0002-3552-3560
Lai, Jimmy Che-To https://orcid.org/0000-0002-5749-1598
Kulkarni, Anand V. https://orcid.org/0000-0002-1240-1675
Premkumar, Madhumita https://orcid.org/0000-0003-2961-4148
Lesmana, Cosmas Rinaldi Adithya
Hsu, Yao Chun https://orcid.org/0000-0001-8984-5103
Huang, Daniel Q. https://orcid.org/0000-0002-5165-5061
- License Information
-
More Information
Article History
Accepted: 10 July 2024
First Online: 15 August 2024
Competing interests
: L.-Y.M. served on the advisory board for Gilead Sciences and Roche Diagnostics. K.C.Y. was a speaker for Gilead and AbbVie, and received a grant supported by the Educate, Test, Treat! Programme, which was funded in part by Gilead Sciences Inc. R.L. has served as an advisory board member for Gilead Sciences, speaker for GenieBiome, and owns equity in Pfizer. J.C.-T.L. served as a speaker for Gilead Sciences, and served on an advisory board committee for Gilead Sciences and Boehringer Ingelheim. Y.C.H. has received research grants from Gilead Sciences, served on advisory committees for Gilead Sciences and Sysmex, and received lecture fees from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Merck Sharp & Dohme and Novartis. D.Q.H. has served on the advisory board for Gilead Sciences and Roche Diagnostics. The other authors have no competing interests to declare.
